CA
IONS icon

CoreCap Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

CoreCap Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3K Hold
370
– – ﹤0.01% 1643
2026
Q1 		$27.8K Hold
370
– – ﹤0.01% 1540
2025
Q4 		$29.3K Buy
370
+325
+722% +$24.5K ﹤0.01% 1531
2025
Q3 		$2.94K Hold
45
– – ﹤0.01% 2300
2025
Q2 		$1.78K Sell
45
-7
-13% -$229 ﹤0.01% 2328
2025
Q1 		$1.57K Buy
52
+7
+16% +$229 ﹤0.01% 2428
2024
Q4 		$1.57K Buy
45
+19
+73% +$710 ﹤0.01% 2286
2024
Q3 		$1.04K Buy
+26
New +$1.21K ﹤0.01% 2266
2024
Q2 		– Sell
-26
Closed -$1.13K – 2086
2024
Q1 		$1.13K Buy
+26
New +$1.24K ﹤0.01% 2208
2022
Q4 		$982 Buy
+26
New +$1.09K ﹤0.01% 2057
2022
Q3 		– Sell
-64
Closed -$2K – 1276
2022
Q2 		$2K Buy
+64
New +$2.41K ﹤0.01% 1872
2022
Q1 		– Sell
-102
Closed -$3K – 1277
2021
Q4 		$3K Buy
+102
New +$3.21K ﹤0.01% 1875

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

CoreCap Advisors's IONS Position: Q2 2026 in Review

CoreCap Advisors held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 370 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1643.

CoreCap Advisors first reported a position in IONS in Q4 2021 and has held it in 12 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • CoreCap Advisors held 370 shares of Ionis Pharmaceuticals worth $29.3K as of Q2 2026.
  • CoreCap Advisors left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1643 holding.
  • CoreCap Advisors first reported a position in Ionis Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.